Kostas Biliouris
Stock Analyst at Oppenheimer
(1.08)
# 3,945
Out of 5,154 analysts
64
Total ratings
34.62%
Success rate
-17.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PEPG PepGen | Initiates: Outperform | $15 | $5.69 | +163.85% | 1 | Feb 25, 2026 | |
| KRRO Korro Bio | Upgrades: Outperform | $22 | $11.18 | +96.78% | 4 | Jan 28, 2026 | |
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $40 → $62 | $25.95 | +138.92% | 7 | Dec 10, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $50 | $16.71 | +199.22% | 9 | Sep 22, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $450 → $470 | $320.66 | +46.57% | 6 | Sep 8, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $40 → $70 | $74.04 | -5.46% | 3 | Sep 3, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | $15 → $4 | $1.38 | +189.86% | 1 | Jul 8, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $30 → $8 | $4.41 | +81.41% | 2 | May 28, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $14.86 | +236.47% | 1 | Mar 12, 2025 | |
| SLN Silence Therapeutics | Maintains: Outperform | $67 → $25 | $6.23 | +301.28% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $50 | $13.44 | +272.02% | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $4.61 | +637.53% | 3 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $17 | $1.48 | +1,048.65% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $40 | $8.48 | +371.70% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $18.97 | +374.43% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $26.54 | +114.77% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $65.36 | -43.39% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $61.12 | +63.61% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $4.01 | +373.82% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $56.50 | +73.45% | 1 | Jun 17, 2022 |
PepGen
Feb 25, 2026
Initiates: Outperform
Price Target: $15
Current: $5.69
Upside: +163.85%
Korro Bio
Jan 28, 2026
Upgrades: Outperform
Price Target: $22
Current: $11.18
Upside: +96.78%
Centessa Pharmaceuticals
Dec 10, 2025
Maintains: Outperform
Price Target: $40 → $62
Current: $25.95
Upside: +138.92%
Sarepta Therapeutics
Sep 22, 2025
Upgrades: Outperform
Price Target: $50
Current: $16.71
Upside: +199.22%
Alnylam Pharmaceuticals
Sep 8, 2025
Maintains: Outperform
Price Target: $450 → $470
Current: $320.66
Upside: +46.57%
Ionis Pharmaceuticals
Sep 3, 2025
Upgrades: Outperform
Price Target: $40 → $70
Current: $74.04
Upside: -5.46%
Jasper Therapeutics
Jul 8, 2025
Downgrades: Market Perform
Price Target: $15 → $4
Current: $1.38
Upside: +189.86%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Outperform
Price Target: $30 → $8
Current: $4.41
Upside: +81.41%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $14.86
Upside: +236.47%
Silence Therapeutics
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $6.23
Upside: +301.28%
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $13.44
Upside: +272.02%
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $4.61
Upside: +637.53%
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.48
Upside: +1,048.65%
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $8.48
Upside: +371.70%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $18.97
Upside: +374.43%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $26.54
Upside: +114.77%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $65.36
Upside: -43.39%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $61.12
Upside: +63.61%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $4.01
Upside: +373.82%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $56.50
Upside: +73.45%